View on GitHub

Added entries:

  • (FDA) ALK-EML4 and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
  • (Clinical trial) BRCA1 and BRCA2 germline variants and sensitivity to olaparib.
  • (Clinical evidence) BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
  • (Clinical evidence) CDKN2A deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
  • (Clinical evidence) MYOCD amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
  • (Preclinical) RB1 copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
  • (Preclinical) RB1 knockout and resistance to palbociclib in prostate cancer.
  • (Preclinical) USP11 silencing and sensitivity to olaparib in osteosarcoma.
  • (Inferential) ATRX copy number deletions and poor prognosis in leiomyosarcoma.
  • (Inferential) BRCA1 and BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
  • (Inferential) CDKN2C deletion may confer sensitivity to CDK4/6 inhibitors.
  • (Inferential) MAP2K4 and MAPK7 copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.
  • (Inferential) PDGFRA copy number amplification and poor prognosis in breast cancer.
  • (Inferential) PTEN copy number deletion and poor prognosis in uterine leiomyosarcoma.
  • (Inferential) PTEN copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma.